Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tresiba (insulin degludec) for the Treatment of Type 1 and Type 2 Diabetes

Drug (Brand / Generic)

Tresiba (insulin degludec)

Company / Licensee

Novo Nordisk

Therapy Class

Long-acting human insulin analogue

Current Indication

Type 1 and Type 2 diabetes

Market Sector

Diabetes

Development Status

Approved in the US and Europe
Expand

Go Top